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Mary Barria, BS a; Khawar Siddiqui, MSc a; Saleh AlMesfer, MD d; Hind Alkatan, MD cAbstractPurpose: To evaluate the efficacy of a 2-drug chemotherapy regimen without external-beam radiotherapy (EBRT) and/or without
enucleation in bilateral retinoblastoma.
Methods: From 1996 to 2010, 79 patients were diagnosed with bilateral RB and were eligible for chemotherapy. Chemotherapy
was administered prior to and/or following local therapy to the eye. All patients received 3 cycles of chemo-reduction with carbo-
platin and vincristine, additional cycles of the same or other chemotherapy, local therapy, EBRT and enucleation were determined
according to re-evaluation by the ophthalmologist.
Results: Advanced disease was seen in 115 (79%) eyes (group IV and V: 96, Group D and E: 19) out of 146 affected eyes. Tumor
response after chemotherapy was observed in 78 patients (98.7%); complete response in 25 (32.1%), partial response in 49 (62.8%)
Four (5.1%) had progressive disease. A total of 50 (63.3%) patients required EBRT; 38 for persistent disease, 4 for progressive dis-
ease, 2 for new lesions, 2 for re-activation and 4 for disease control. Enucleation was required in 15 (19%). Secondary malignancies
occurred in two patients who underwent EBRT; one osteogenic sarcoma and one rhabdomyosarcoma then later osteogenic sar-
coma. The 10 year overall survival was 96.3% with a median follow-up time of 3.124 ± 0.536 years (95%CI: 2.074–4.174).
Conclusions: The 2-drug chemotherapy regimen combined with local therapy appears to be adequate therapy for low stage dis-
ease but not in patients with advanced disease. The occurrence of secondary cancers in this group of patients is worrisome further
highlighting the deleterious effects of EBRT.
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Retinoblastoma is the most common cancer of the eye in
children, affecting 1 in 15,000 live births. If untreated, it is
fatal, but with timely detection and multidisciplinary care
using current technology and treatment protocols, more than95% of patients can be successfully salvaged before the dis-
ease spreads outside the eye.1–3
The primary goal of therapy is to save the child’s life. How-
ever, retaining the affected eye, preserving vision, and good
cosmetic results are also important. Classification of retino-
blastoma is important to determine appropriate therapy fore:
al.com
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come.4 The Reese–Ellsworth (R–E) classification was devised
to predict the outcome of eyes treated with external beam
radiotherapy (EBRT). The long-term complications of radia-
tion for children with retinoblastoma constitutional mutations
include a high lifelong risk of secondary non-retinoblastoma
malignancies with poor survival rates. The International intra-
ocular retinoblastoma classification (IIRC) was developed for
prognosis of eyes with intraocular retinoblastoma treated
with chemotherapy and/or focal therapy.4
Current treatments for intraocular retinoblastoma include
enucleation, external beam radiation therapy, cryotherapy,
laser photocoagulation, thermotherapy, brachytherapy with
iodine 125 or ruthenium 106 plaques, subconjunctival chemo-
therapy, intra-arterial chemotherapy and systematic chemo-
therapy.5 Chemotherapy and focal therapy have replaced
EBRT as the primary treatment worldwide.5,6 The goal of che-
motherapy is to reduce the tumor volume for focal therapy
(with cryotherapy, laser, thermotherapy, or plaque brachy-
therapy). For small, localized tumors (group A under the
international classification system), focal consolidative ther-
apy alone is effective with one study demonstrating 86% of
tumors having lasting regression.7 Most chemotherapy pro-
tocols for larger tumors use 2-or 3-drug chemotherapy with
Carboplatin, Etoposide, and Vincristine.8 Due to the fact that
children with germ line retinoblastoma are at a higher risk of
developing secondary tumors, we opted not to include eto-
poside in the chemo-reduction regimen for children with ret-
inoblastoma as first line therapy. This review outlines our
experience with a 2-drug regimen utilizing Vincristine and
Carboplatin as chemo-reduction in children with
retinoblastoma.Patients and methods
This research study was reviewed and approved by the
Institutional Review Board of King Faisal Specialist Hospital
and Research Centre, Riyadh, Saudi Arabia, Office of the Re-
search Affairs.
Treating facilities
King Khalid Eye Specialist Hospital (KKESH) is a Tertiary
Center situated in Riyadh, Saudi Arabia. Most patients with
retinoblastoma in the Kingdom are referred to KKESH where
they are diagnosed, and their disease is classified and
staged; therapy is then administered as deemed necessary
by the ocular oncologists. Children diagnosed with retinobl-
astomas that are eligible for systemic chemotherapy and/or
external beam radiation therapy are referred to the King Fai-
sal Specialist Hospital and Research Center (KFSH&RC) for
further management. When patients are seen in KFSH&RC,
pathology is confirmed and further work-up and staging are
performed as deemed necessary.
Retinoblastoma team
The retinoblastoma team is comprised of the ocular oncol-
ogists, opthalmo-pathologist and retinoblastoma coordina-
tor in KKESH and the pediatric hematologist/oncologist,
clinical nurse coordinator and radiation oncologist in
KFSH&RC.Patient population and study design
From 1996 to 2007 the Reese–Ellsworth (R–E) classification
was used for children less than 14 years of age with retino-
blastoma and from 2008 onward the International Intraocular
Retinoblastoma Classification was adopted. Patients with Re-
ese–Ellsworth (R–E) classification groups I, or International
Intraocular Retinoblastoma Classification group A were not
eligible for chemotherapy. Patients eligible for chemo-reduc-
tion were those with Reese–Ellsworth (D–E) classification, or
International Intraocular Retinoblastoma Classification group
B–E; patients with advanced disease received adjuvant che-
motherapy. The chemo-reduction regimen consisted of Vin-
cristine and Carboplatin given every 3 weeks for a total of 6
cycles. The number of cycles ranged from 2 to 9, depending
on the examination of the patients and further recommenda-
tions from the ocular oncologists. Patients were assessed fol-
lowing 2 cycles of chemo-reduction by the ocular oncologists
for further intervention mainly focal therapy and continuation
of chemo-reduction. At the end of therapy, patients were re-
assessed; if there was complete response, no further therapy
was delivered. If, however, the response was not satisfactory
with progression, re-activation, or new lesions, then further
therapeutic options including enucleation, external beam
radiation therapy, and further chemotherapy were deter-
mined by the ocular oncologists.Results
From January 1996 to January 2010, a total of 79 patients
were diagnosed with bilateral retinoblastoma and were eligi-
ble for chemo-reduction; they are the subject of this study.
Median age at diagnosis was 0.9 years (Mean ± SEM:
1.27 ± 0.13, Min: 0.1-Max: 7.1), and 50.6% were male. Fe-
males presented at an earlier median age of 0.79 years
(Mean ± SEM: 1.22 ± 0.20) compared to males at 0.94 years
(Mean ± SEM: 1.32 ± 0.17), but this difference was not statis-
tically significant (p = 0.505, Mann–Whitney U Test). Sixty-five
patients (82.3%) presented with various signs and symptoms;
39 had leukocoria (median duration: 8 weeks), 8 had squint
(median duration: 20 weeks), 8 had poor vision (median dura-
tion: 8 weeks), 3 had white reflex, 2 had orbital cellulitis and 2
had esotropia. Other symptoms such as red eye, abnormal
red reflux, cat’s eye, eye lesion and no light perception were
uncommonly seen; 1 each in our patient population. Ad-
vanced disease was seen in 115 (79%) eyes (Group IV–V:
96, Group D–E: 19) out of 146 affected eyes. Detailed infor-
mation on staging is provided in Table I.
Tumor response after chemotherapy was observed in 78
patients (98.7%); complete response in 25 (32.1%), partial re-
sponse in 49 (62.8%) and progressive disease in 4 (5.1%). A
total of 50 patients (63.3%) required EBRT; 38 for persistent
disease, 4 for progressive disease, 2 for new lesions, 2 for re-
activation and 4 for disease control. Enucleation was required
in 15 (19%). Secondary malignancies were seen in 2 patients
who underwent EBORT; 1 patient developed osteogenic sar-
coma and the other rhabdomyosarcoma then osteogenic sar-
coma. Median time to develop secondary malignancy was
20.9 months from discontinuation of therapy. Sixty-eight of
our patients (86.1%) were on follow-up after finishing
treatment, 7 (8.9%) were lost to follow-up, 1 (1.3%) was re-
ferred to another hospital for continuation of treatment and
Table I. The staging details of all patients.
Stage Left Eye Right Eye
% (n) % (n)
Reese-Ellsworth Classification
I a 1.4 (1) 0 (0)
I b 1.4 (1) 1.4 (1)
II a 6.8 (5) 1.4 (1)
II b 2.7 (2) 2.8 (2)
III a 4.1 (3) 8.3 (6)
III b 1.4 (1) 5.6 (4)
VI a 2.7 (2) 2.8 (2)
VI b 5.4 (4) 2.8 (2)
V a 10.8 (8) 8.3 (6)
V b 47.3 (35) 51.4 (37)
ICRB
Group A 2.7 (2) 0 (0)
Group B 0 (0) 1.4 (1)
Group C 0 (0) 1.4 (1)
Group D 5.4 (4) 9.7 (7)
Group E 8.1 (6) 2.8 (2)
Total 93.7 (74) 91.1 (72)
Note: For 79 patients, information on 74 left and 72 right eyes was available. Staging
was not done if either the eye was not affected or there was no eye present.
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the secondary malignancies. The 12-year overall survival
(Fig. 1) was 96.3% with a median follow-up time of
3.124 ± 0.536 years (95%CI: 2.074–4.174).
Discussion
Management of a child with retinoblastoma requires a
multidisciplinary approach including ophthalmologists, pedi-
atric oncologists, radiation oncologists, and many others that
play important roles in the cure of the disease1–8 The current
available therapeutic options are numerous, and the indica-
tions to use specific modality or a combination of modalities
vary according to the extent of the disease6–8 Most patients
with unilateral disease present with advanced intraocular dis-
ease and therefore usually undergo enucleation, which re-
sults in a cure rate >95%9–11 On the other hand, children
with bilateral disease at diagnosis usually require multimodal-
ity therapy (chemotherapy, local therapies)12–14. Failure to
control disease in children with bilateral disease may lead
to external beam radiation EBRT and/or enucleation.15Figure 1. Overall survival of all patients who underwent chemoreduction
at KFSHRC.Several studies have established that chemotherapy is very
effective in eliminating the need for EBRT/enucleation in R-
E group I–III eyes, but the experience with eyes with group
IV or V disease has been significantly less rewarding; the che-
motherapy regimen commonly used consists of carboplatin,
vincristine, and etoposide.14,16,17
Secondary neoplasms in patients with retinoblastoma
have been well recognized since the 1960’s. The majority oc-
cur in patients with bilateral disease who are exposed to
EBRT after a prolonged latent period, but, they may also oc-
cur in patients who did not receive radiation therapy10,18–22.
Etoposide is an anti- DNA topoisomerase II agent that has
been widely used for the treatment of many types of cancers
in children including retinoblastoma and has been associated
with an increased risk of secondary leukemia specifically
acute myeloid leukemia23,24. Though the incidence of sec-
ondary acute myeloid leukemia is rare, there are several re-
ports of its occurrence in retinoblastoma patients.24,25
Because of the potentially increased risk for secondary malig-
nancies when using etoposide26, in this study, we, like many
others, opted for the 2-drug regimen consisting of Vincristine
and Carboplatin at standard schedules and doses. Although
this therapy was well tolerated with acceptable toxicity,
many of the patients with advanced disease with the Re-
ese–Ellsworth (R–E) classification group IV and V and patients
with advanced disease using the International Intraocular
Retinoblastoma Classification including group D and E re-
quired enucleation and/or external beam radiation therapy.
This has been previously demonstrated in other studies utiliz-
ing chemo-reduction in an attempt to avoid enucleation or
the need of EBRT. In a study by Friedman27, 47 patients were
treated with 6 cycles of vincristine, etoposide and carbo-
platin along with focal therapy in the majority of patients;
for patients with less advanced disease, i.e. R–E group I–III,
no enucleation or EBRT was necessary while in patients with
advanced disease, i.e. R–E group IV and V, 33% of six eyes
and 53% of 30 eyes, respectively, required EBRT and/or
enucleation with the conclusion that more effective therapy
is required for R–E group IV and V. Shields reported their
results on 103 patients, 158 eyes, 75 (48%) eyes were R–E
group V, 47% required EBRT while 53% underwent enucle-
ation compared to lower stage disease patients in whom
only 10% required EBRT and only 15% required enucleation.
Murphee et al.28 also reported on 136 patients (172 eyes)
who were treated and followed-up from 1990 to 1995;
initially, the patients were treated with carboplatin and
thermochemotherapy from 1990–1992, and after 1992 pa-
tients were treated with 3 monthly cycles of chemoreduction
with vincristine, etoposide and carboplatin followed by
sequential aggressive local therapy. Patients underwent eye
examinations under anesthesia every 2–3 weeks. In patients
with RE I–II thermochemotherapy was successful for larger
tumors in the absence of vitreous or extensive subretinal
seeding, 3 cycles of chemoreduction followed by sequential
aggressive local therapy eradicates the residual viable tumor.
In this study of Saudi patients, the use of a 2-drug regimen
did not seem to lessen the need for the use of ERBT or enu-
cleation, corroborating the already published international
data as discussed above. We have, consequently, modified
our chemotherapy management for patients with the Interna-
tional classification group D and E to a 3-drug regimen
containing vincristine, carboplatin and etoposide.
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